Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$21.63 - $57.65 $726,768 - $1.94 Million
-33,600 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$11.0 - $28.24 $149,600 - $384,064
13,600 Added 68.0%
33,600 $844,000
Q4 2020

Feb 16, 2021

SELL
$10.12 - $13.94 $50,599 - $69,700
-5,000 Reduced 20.0%
20,000 $240,000
Q3 2020

Nov 13, 2020

BUY
$9.93 - $13.47 $248,250 - $336,750
25,000 New
25,000 $250,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $745M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Sg3 Management, LLC Portfolio

Follow Sg3 Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.